Evidence map›Paper›PMID 41539306›Full record

ArticleMolecular cell2026

Dominant-negative TP53 mutations potentiated by the HSF1-regulated proteostasis network.

Stephanie Halim, Rebecca M Sebastian, Kristi E Liivak, Jessica E Patrick, Tiffani Hui, David R Amici, Andrew O Giacomelli, Paulina Rios, Vincent L Butty, William C Hahn and 4 more

Abstract read
In one paragraph

Article in Molecular cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Stephanie HalimDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Rebecca M SebastianDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kristi E LiivakDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jessica E PatrickDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Tiffani HuiDepartment of Chemistry, Tufts University, Medford, MA 02155, USA.
David R AmiciDepartment of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Medical Scientist Training Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Andrew O GiacomelliHumber Polytechnic, Toronto, ON M9W 5L7, Canada.
Paulina RiosKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Vincent L ButtyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; BioMicro Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
William C HahnDana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Francisco J Sánchez-RiveraKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Marc L MendilloDepartment of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Yu-Shan LinDepartment of Chemistry, Tufts University, Medford, MA 02155, USA.
Matthew D ShouldersDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: mshoulde@mit.edu.

Funding

Mutant p53 in Tumorigenesis, Invasion, and MetastasisP01CA291694 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI James J Manfredi · 2025 to 2026
$7.9M
Defining the Interplay Between Viral Adaptation and Host ProteostasisR01AI168166 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Matthew Donald Shoulders · 2022 to 2026
$2.9M
Leveraging Next-Generation Directed Evolution Platforms and Chemical Control of Proteostasis to Deliver Robust Biotechnologies and Illuminate Roles of Chaperone Networks in Protein EvolutionR35GM136354 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHOULDERS, MATTHEW DONALD · 2020 to 2024
$2.1M
Investigating Rational Combination Therapies for Triple-Negative Breast CancerR01CA258833 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Marc Mendillo · 2022 to 2026
$1.7M
Regulation and interplay of Heat Shock Factors in growth-associated proteotoxic stressesR01GM144617 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Marc Mendillo · 2022 to 2026
$1.6M
Genetic Map of the Mammalian Cell Response to Environmental StressR21ES035975 · NIEHS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MENDILLO, MARC · 2024 to 2024
$440k
NCI NIH HHS P01 CA291694NCI NIH HHS R01 CA258833NIAID NIH HHS R01 AI168166NIEHS NIH HHS R21 ES035975NIGMS NIH HHS R01 GM144617NIGMS NIH HHS R35 GM136354
6 · The paper itself

Abstract

Protein mutational landscapes are shaped by how amino acid substitutions affect stability and folding or aggregation kinetics. These properties are modulated by cellular proteostasis networks. Heat shock factor 1 (HSF1) is the master regulator of cytosolic and nuclear proteostasis. Chronic HSF1 activity upregulation is a hallmark of cancer cells, potentially because upregulated proteostasis factors facilitate the acquisition and maintenance of oncogenic mutations. Here, we assess how HSF1 activation influences mutational trajectories by which p53 can escape cytotoxic pressure from nutlin-3, an inhibitor of the p53 regulator mouse double minute 2 homolog (MDM2). HSF1 activation broadly increases the fitness of dominant-negative p53 substitutions, particularly non-conservative, biophysically unfavorable amino acid changes within buried regions of the p53 DNA-binding domain. These findings demonstrate that HSF1 activation reshapes the oncogenic mutational landscape by preferentially supporting the emergence and persistence of biophysically disruptive, cancer-associated p53 substitutions, linking proteostasis network activity directly to oncogenic evolution.

Indexed as

Heat Shock Transcription FactorsMutationProteostasisTumor Suppressor Protein p53Amino Acid SubstitutionAnimalsCell Line, TumorHumansImidazolesPiperazinesProteotoxic StressProto-Oncogene Proteins c-mdm2Heat Shock Transcription FactorsHSF1 protein, humanImidazolesMDM2 protein, humannutlin 3PiperazinesProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53cancer evolutionchaperonesdeep mutational scanningheat shock factor IHSP70HSP90mutational bufferingp53protein foldingproteostasis

Identifiers

PMID41539306
PMCPMC12917913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.